Let’s
Outdo
Cancer
A world where people with cancer live better and longer lives—that’s our vision. We are accelerating breakthrough medicines that bring new hope to patients everywhere.
Cancer updates & breakthroughs
How antibody-drug conjugates (ADCs) might change treatment
Antibody-drug conjugates are changing the landscape of cancer treatments.
Watch Patrick Dempsey talk with real people affected by cancer
See how our Change the Odds initiative with the American Cancer Society highlights the importance of breaking down barriers for rural communities.
Treatment resistance: One of oncology’s challenges
Learn how researchers are working to address this challenge in cancer treatment.
Inside Pfizer oncology innovation with a lead treatment developer
Meet Dr. O’Meara, Pfizer’s Head of Early Stage Development, and learn about her journey as a woman in a male-dominated field.
Advancing
science
Dive into our research and how we’re making strides against cancer.
Explore our expertise in major cancer types
Lung cancer
Advancements in research and earlier detection have helped improve lung cancer survival rates.
Breast cancer
We’re focused on redefining what’s possible in breast cancer care.
Colorectal cancer
Advancements in precision medicine are transforming colorectal cancer treatment.
Prostate cancer
We are committed to reshaping the future of prostate cancer care through innovative therapies and support.
Building on a legacy of breakthroughs
With a history of bringing transformative medicines to the world, Pfizer is continuing to make strides in the fight against cancer. Today, approximately 40% of our research and development (R&D) investment is focused on advancing innovative cancer therapies.
Explore our milestones.
2024
New phase 3 clinical trials started for new potential medicines in lung, breast, and prostate cancer
2024
Clinical trial results in ALK (anaplastic lymphoma kinase) -positive non-small cell lung cancer (NSCLC), representing a potential advancement in lung cancer treatment
2023
Seagen becomes part of Pfizer, bringing world-leading ADC technology to Pfizer and doubling the number of clinical trials in cancer
2023
Bispecific antibody medicine that harnesses the body’s immune system to treat advanced multiple myeloma is approved
2023
Groundbreaking clinical trial results of a combination antibody-drug conjugate (ADC) and immunotherapy demonstrate the potential to change how advanced bladder cancer is treated
2023
A medicine that inhibits the poly (ADP-ribose) polymerase (PARP) protein on cancer cells combined with existing medicines to treat an advanced form of prostate cancer is approved
2020
The first medicine that precisely targets colorectal cancer (CRC) cells that are positive for a specific gene mutation that plays a critical role in CRC is approved
2018
ALK-positive lung cancer medicine, which overcomes common mutations that are known to stop other medicines from working, is approved
2015
Innovative medicine for people with metastatic breast cancer (mBC) is approved, marking the first advancement in mBC in more than 10 years
2011
First-ever medicine to inhibit the abnormal ALK proteins in lung cancer is approved
Accelerating breakthroughs
Every minute matters with 50+ programs in development and more than 25 potential approvals in the next 5 years. Pfizer is delivering new cancer treatments, prioritizing innovative therapies that could make an impact.
Video_id: 6353406732112
Antibody-drug conjugates
Antibody-drug conjugates (ADCs) are a type of targeted treatment designed to deliver cancer-killing medicine directly to tumors.
Video_id: 6353405643112
Bispecifics
Bispecific antibodies are designed to connect immune cells (called T-cells) with cancer cells to help the body’s immune system find and destroy the cancer.
Video_id: 6353405160112
Small molecules
Pfizer’s targeted therapies include oral medicines that are small enough to easily enter cancer cells and targeted to slow or stop cancer growth.
Advancing treatments
together
Tomorrow’s cancer treatments are being developed in today’s clinical trials. When you participate, you’re making it possible to potentially bring breakthrough medicines to people living with cancer.
Stories of
strength
Discover the inspiring stories
of real people living with cancer.
video_id: 6365867268112
Change the Odds
When it comes to cancer, the odds seem stacked against certain communities. At Pfizer, we are proud to partner with the American Cancer Society on a new program to help change that.
video_id: 6365868327112
Lynce’s story | Multiple myeloma
How her journey led to finding her voice and empowering others living with multiple myeloma.
video_id: 6365904116112
Tom's story | Prostate cancer
How Tom has become an advocate for the prostate cancer community, emphasizing the importance of continued patient education and living life to its fullest.